In October 2024 ATB Therapeutics Raises €54 Million Series A Financing

ATB Therapeutics Raises €54 Million Series A Financing to Propel Innovative Antibody Payload Technology into Clinical Development. The Financing is co-led by EQT Life Sciences and MRL Ventures Fund (MRLV, corporate venture arm of Merck & Co., Inc., Rahway, N.J., USA), alongside contributions from V-Bio Ventures, VIVES Partners, the Belgian sovereign fund SFPIM, Wallonie Entreprendre, Sambrinvest, and historical inverstors.